Immune Responses to Plasmodium falciparum Malaria

The immune response to Plasmodium falciparum malaria encompasses a complex interplay between innate and adaptive systems, tailored to each stage of the parasite’s life cycle. During the pre-erythrocytic phase in the liver, innate cells such as dendritic cells and natural killer cells produce cytokines that shape downstream T-cell responses. Once merozoites enter the bloodstream, humoral immunity becomes critical: antibodies of various isotypes bind merozoite surface proteins to neutralise invasion, fix complement, or engage Fcγ receptors on phagocytes. Cytophilic IgG subclasses and IgM can mediate opsonic phagocytosis and trigger production of reactive oxygen species for parasite killing. Complement deposition amplifies antibody-mediated inhibition of erythrocyte invasion. Concurrently, CD4+ T helper cells secrete interferon-γ and support B-cell maturation, while CD8+ T cells contribute to cytotoxic clearance of infected hepatocytes in early infection. Memory B and T cells provide longer-term protection, though repetitive natural exposure is often required to achieve clinical immunity. Unravelling these mechanisms informs vaccine design and guides evaluation of novel immunogens and functional assays in controlled human malaria challenge studies worldwide.

Research from Nature Portfolio

Recent studies have defined key innate effector pathways that underpin naturally acquired immunity. Work on blood phagocytes has shown that neutrophils, upon engagement of FcγRIIA and FcγRIIIB by IgG-opsonised merozoites, generate intracellular and extracellular reactive oxygen species through NADPH oxidase 2 and PI3K signalling. High neutrophil ROS responses were associated with protection against febrile malaria in geographically distinct cohorts. Complement-fixing antibodies against merozoite antigens have also been dissected to identify targets that correlate most strongly with protective immunity. Quantitative analyses demonstrated that antigen-specific complement fixation by antibodies exceeds growth-inhibition assays in predicting resistance to clinical malaria. Modelling of combinations of three key merozoite antigens suggests that multi-antigen vaccine formulations could achieve over 95% efficacy in blocking blood-stage replication.

Immune Responses to Plasmodium falciparum Malaria publication trend

The graph below shows the total number of articles in immune responses to plasmodium falciparum malaria across all publications each year (not limited to Nature Index journals).

Technical terms

Merozoite: The blood-stage, invasive form of Plasmodium falciparum that infects red blood cells.

Opsonic phagocytosis: The process by which antibodies coat pathogens, promoting their uptake and destruction by phagocytes.

Reactive oxygen species (ROS): Chemically reactive molecules produced by phagocytes that contribute to intracellular pathogen killing.

Fcγ receptor: A cell-surface receptor on immune cells that recognises the Fc region of IgG antibodies, triggering effector functions.

Complement fixation: The binding of complement proteins to antibody-pathogen complexes, leading to membrane attack and enhanced phagocytosis.

Cytophilic IgG: IgG subclasses (IgG1 and IgG3) that efficiently bind to Fcγ receptors and mediate phagocytosis and other effector functions.

References

1. Breadth of Fc-mediated effector function correlates with clinical immunity following human malaria challenge. Immunity (2024).
2. Multifunctional IgG/IgM antibodies and cellular cytotoxicity are elicited by the full-length MSP1 SumayaVac-1 malaria vaccine. npj Vaccines (2023).
3. High opsonic phagocytosis activity and growth inhibition of merozoites are associated with RON4 antibody levels and protect against febrile malaria in Ghanaian children. Frontiers in Immunology (2023).
4. Human blood neutrophils generate ROS through FcγR-signaling to mediate protection against febrile P. falciparum malaria. Communications Biology (2023).
5. Targets of complement-fixing antibodies in protective immunity against malaria in children. Nature Communications (2019).